Gyros AB Appoints Dr. Henrik Bjorkman as CTO and VP Technical Affairs
As part of his new role at Gyros, Henrik will have responsibility for driving strategic and operational decisions, managing product development, intellectual property, manufacturing, QA, and QC, and will oversee the existing product range. As part of the executive management team Henrik will work closely with marketing and sales departments, reporting to the board of directors.
Henrik joins Gyros from GE Healthcare Life Sciences, where he was most recently Director, MicroCal R&D, leading the MicroCal operation in Northampton, MA. He has many years of experience in senior positions within R&D, technical and management roles, at a range of life science companies from small organizations to larger, industrial enterprises. Henrik holds a PhD in Materials Science and Micro Engineering from Uppsala University.
“The technology developed at Gyros offers an exciting step forward for the biopharmaceutical community,” said Henrik. “I am excited to have the opportunity to support the continued success of the Gyros immunoassay platform.”
Erik Walldén, CEO at Gyros, commented: “We welcome Henrik to Gyros, and look forward to working with him. Bringing extensive experience in product development and manufacturing for globalized, commercial organizations in the life science tools industry, Henrik will be a great asset for the continued development of our microfluidic immunoassay technology.”
Enquiries:
Katie Odgaard
Zyme Communications Ltd
Tel: +44 (0) 7787 502 947
Email: katie.odgaard@zymecommunications.com
Twitter: zymecomms
About Gyros AB www.gyros.com
Gyros AB is the world leader in utilization of microfluidic technologies to miniaturize and automate immunoassays. The Gyros™ immunoassay platform increases productivity and efficiency during development of biotherapeutics and vaccines, saving time and labor. Major biopharmaceutical companies and their service providers utilize the Gyros platform to boost time-critical workflows and meet increasing regulatory demands.
Spanning the entire spectrum of immunoassays, the platform cuts the time to result significantly. Faster development times, and unattended running of assays at nanoliter scale, save labor and sample. The ease of assay transfer between sites and from development to regulated environments is unsurpassed in the industry.
The company is, based in Uppsala, Sweden and has regional sales and support offices in the USA and Europe, and a growing network of distributors in Asia Pacific.